Bosutinib – an effective and safe treatment option in the management of chronic myeloid leukemia

Imatinib is the first tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia (CML) and TKIs are the mainstay of CML treatment (1). Subsequently in the BFORE trial, where 400mg bosutinib was compared with imatinib 400mg in the first-line treatment of patients with CML-...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2020-01, Vol.16 (3), p.4425-4428
Main Authors: Ercaliskan, Abdulkadir, Eskazan, Ahmet Emre
Format: Article
Language:English
Subjects:
adverse event
bosutinib
Cardiac arrhythmia
Cardiovascular disease
chronic myeloid leukemia
Clinical trials
Comorbidity
Diabetes
Diarrhea
imatinib
Leukemia
Lung diseases
Mutation
Pancreatitis
Patients
Pulmonary hypertension
Targeted cancer therapy
Thrombocytopenia
tyrosine kinase inhibitor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Imatinib is the first tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia (CML) and TKIs are the mainstay of CML treatment (1). Subsequently in the BFORE trial, where 400mg bosutinib was compared with imatinib 400mg in the first-line treatment of patients with CML-CP, bosutinib 400mg/day displayed both faster and deeper molecular responses as well as superior MMR and CCyR rates over 400mg/day imatinib and the 2-year cumulative MMR and CCyR rates were 68.7and 82.5%, respectively (6). The authors summarized the results of the clinical trials and pharmacological features of bosutinib and highlighted the most important points of TKI selection, especially in elderly CML patients with multiple comorbidities. [...]bosutinib might be a reasonable treatment option, especially for elderly CML-CP patients with comorbidities.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2020-0006